Advertisement

Advertisement

European Lung Cancer Virtual Congress 2021

Lung Cancer
Genomics/Genetics

Patients With NSCLC and Driver Mutations May Be More Likely to Present With Brain Metastasis at Diagnosis

The incidence of brain metastasis at diagnosis in patients with non–small cell lung cancer (NSCLC) harboring driver mutations was high, according to findings presented by Rashkit et al at the European...

Lung Cancer
Genomics/Genetics

Analysis Identifies Frequency of PI3K Pathway Alterations in Patients With NSCLC

A retrospective analysis of patients with non–small cell lung cancer (NSCLC) identified potentially targetable alterations in the PI3K pathway that were not mutually exclusive to mutations in other pa...

Lung Cancer
COVID-19

Incidence of Brain Metastases in Patients Diagnosed With Stage IV NSCLC During the COVID-19 Pandemic

Computed tomography and/or magnetic resonance imaging demonstrated that 39% of patients diagnosed with stage IV non–small cell lung cancer (NSCLC) presented with de novo brain metastases during the CO...

Lung Cancer
Issues in Oncology

Some Patients With Lung Cancer Report Feeling Uninformed About Their Disease, Uninvolved With Their Treatment

More than 1 in 10 patients with lung cancer do not know what type of tumor they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition (GLCC) presented by Beat...

Lung Cancer
Genomics/Genetics

Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC

Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, confirming its role as a therapeu...

Advertisement

Advertisement



Advertisement